Literature DB >> 25280671

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

Marko Skrtić1, Gary K Yang, Bruce A Perkins, Nima Soleymanlou, Yuliya Lytvyn, Maximilian von Eynatten, Hans J Woerle, Odd Erik Johansen, Uli C Broedl, Thomas Hach, Melvin Silverman, David Z I Cherney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25280671     DOI： 10.1007/s00125-014-3396-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Evaluation of renal resistances, with special reference to changes in essential hypertension.

Authors:  D M GOMEZ
Journal:  J Clin Invest       Date:  1951-10       Impact factor: 14.808

2.  Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Authors:  Linda F Fried; Nicholas Emanuele; Jane H Zhang; Mary Brophy; Todd A Conner; William Duckworth; David J Leehey; Peter A McCullough; Theresa O'Connor; Paul M Palevsky; Robert F Reilly; Stephen L Seliger; Stuart R Warren; Suzanne Watnick; Peter Peduzzi; Peter Guarino
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

3.  Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten
Journal:  Circulation       Date:  2013-12-13       Impact factor: 29.690

4.  Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus.

Authors:  P T Luik; K Hoogenberg; F G H Van Der Kleij; B J Beusekamp; M N Kerstens; P E De Jong; R P F Dullaart; G J Navis
Journal:  Diabetologia       Date:  2002-04       Impact factor: 10.122

5.  Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.

Authors:  V Vallon; K Richter; R C Blantz; S Thomson; H Osswald
Journal:  J Am Soc Nephrol       Date:  1999-12       Impact factor: 10.121

Review 6.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

7.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

Authors:  Bruce A Perkins; David Z I Cherney; Helen Partridge; Nima Soleymanlou; Holly Tschirhart; Bernard Zinman; Nora M Fagan; Stefan Kaspers; Hans-Juergen Woerle; Uli C Broedl; Odd-Erik Johansen
Journal:  Diabetes Care       Date:  2014-03-04       Impact factor: 19.112

9.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

10.  The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Authors:  David Zi Cherney; Bruce A Perkins; Nima Soleymanlou; Ronnie Har; Nora Fagan; Odd Erik Johansen; Hans-Juergen Woerle; Maximilian von Eynatten; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2014-01-29       Impact factor: 9.951
  10 in total
  48 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

Review 2.  Acute kidney injury from SGLT2 inhibitors: potential mechanisms.

Authors:  Kai Hahn; A Ahsan Ejaz; Mehmet Kanbay; Miguel A Lanaspa; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2016-11-16       Impact factor: 28.314

Review 3.  The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.

Authors:  Merlin C Thomas; David Z I Cherney
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

4.  Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Authors:  Christoph Wanner; Hiddo J L Heerspink; Bernard Zinman; Silvio E Inzucchi; Audrey Koitka-Weber; Michaela Mattheus; Stefan Hantel; Hans-Juergen Woerle; Uli C Broedl; Maximilian von Eynatten; Per-Henrik Groop
Journal:  J Am Soc Nephrol       Date:  2018-10-12       Impact factor: 10.121

5.  Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report.

Authors:  Gautam Phadke; Amit Kaushal; Dean R Tolan; Kai Hahn; Thomas Jensen; Petter Bjornstad; Carlos Roncal-Jimenez; Ana Andres Hernando; Miguel A Lanaspa; Mariam Priya Alexander; Aleksandra Kukla; Richard J Johnson
Journal:  Am J Kidney Dis       Date:  2020-05-05       Impact factor: 8.860

Review 6.  A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.

Authors:  Martin C Michel; Eric Mayoux; Volker Vallon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-26       Impact factor: 3.000

7.  Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.

Authors:  Julie A Lovshin; Geneviève Boulet; Yuliya Lytvyn; Leif E Lovblom; Petter Bjornstad; Mohammed A Farooqi; Vesta Lai; Leslie Cham; Josephine Tse; Andrej Orszag; Daniel Scarr; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Zi Cherney
Journal:  JCI Insight       Date:  2018-01-11

8.  Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Julie A Lovshin; Genevieve Boulet; Mohammed A Farooqi; Vesta Lai; Josephine Tse; Leslie Cham; Leif E Lovblom; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Andrew Advani; Etienne Sochett; Bruce A Perkins; David Z I Cherney
Journal:  Am J Kidney Dis       Date:  2019-02-22       Impact factor: 8.860

Review 9.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

10.  Influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes.

Authors:  Marko Škrtić; Yuliya Lytvyn; Petter Bjornstad; Heather N Reich; James W Scholey; Paul Yip; Etienne B Sochett; Bruce Perkins; David Z I Cherney
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.